

**IN THE CLAIMS:**

Please amend claims 24, 25, 34, and 39-42. Please cancel claims 26-32 and 43-44.

This listing of claims will replace all prior versions, and listings, of claims in the application:

**STATUS OF THE CLAIMS:**

24.(Currently Amended) A method for identifying a compound which stimulates or inhibits the activity of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 4, or a fragment thereof, wherein the activity is ~~modulates a 14273 polypeptide activity selected from the group consisting~~ of:

- 1) binding to a G protein in response to ligand binding;
- 2) receptor protein phosphorylation in response to ligand binding;
- 3) binding to a ligand;
- 4) modulation of intracellular calcium concentration;
- 5) modulation of intracellular cAMP concentration;
- 6) modulation of adenylate cyclase activity; and
- 7) modulation of phospholipase C activity,

the method comprising:

- a) contacting a cell expressing ~~thea polypeptide comprising the amino acid sequence of SEQ ID NO:1 or 4, or a fragment thereof,~~ with a test compound under conditions suitable for stimulation or inhibition~~modulation of the 14273 polypeptide activity;~~ and
- b) detecting stimulation or inhibition~~modulation of thea 14273 polypeptide activity~~ by the test compound,

thereby identifying a compound which stimulates or inhibits the activity of the polypeptide.

25.( Currently Amended) A method for identifying a compound which stimulates or inhibits the activity of a polypeptide encoded by the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number PTA-1143, or a fragment thereof, wherein the activity is ~~modulates a 14273 polypeptide activity selected from the group consisting of:~~

- 1) binding to a G protein in response to ligand binding;
- 2) receptor protein phosphorylation in response to ligand binding;
- 3) binding to a ligand;
- 4) modulation of intracellular calcium concentration;
- 5) modulation of intracellular cAMP concentration;

6) modulation of adenylate cyclase activity; and

7) modulation of phospholipase C activity,

the method comprising:

a) contacting a cell expressing thea polypeptide ~~encoded by the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number PTA-1143, or a fragment thereof,~~ with a test compound under conditions suitable for stimulation or inhibition ~~modulation~~ of thea-14273 polypeptide activity; and

b) detecting modulation of thea-14273 polypeptide activity by the test compound,  
thereby identifying a compound which stimulates or inhibits the activity of the polypeptide.

26-32. (Canceled)

33. (Previously Presented)      The method of any one of claims 24 or 25, wherein said cell is a cardiac myocyte.

34. (Currently Amended)      The method of any one of claims 24 or 25, wherein stimulation or inhibition ~~modulation~~ of thea-14273 polypeptide activity by the test compound is detected by detecting a morphological change in said cell.

35. (Previously Presented)      The method of claim 34, wherein said morphological change is cellular hypertrophy.

36. (Previously Presented)      The method of any one of claims 24 or 25, wherein said test compound is a peptide.

37. (Previously Presented)      The method of any one of claims 24 or 25, wherein said test compound is an antibody.

38. (Previously Presented)      The method of any one of claims 24 or 25, wherein said test compound is a small molecule.

39. (Currently Amended)      The method of any one of claims 24 or 25, wherein said compound stimulates thea-14273 polypeptide activity.

40. (Currently Amended) The method of any one of claims 24 or 25, wherein said compound inhibits ~~thea-14273~~ polypeptide activity.

41. (Currently Amended) A method for identifying a compound which stimulates or inhibits the activity of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or 4, or fragment thereof, wherein the activity is ~~modulates a 14273 polypeptide activity selected from the group consisting of:~~

- 1) binding to a G protein in response to ligand binding;
- 2) receptor protein phosphorylation in response to ligand binding;
- 3) binding to a ligand;
- 4) modulation of intracellular calcium concentration;
- 5) modulation of intracellular cAMP concentration;
- 6) modulation of adenylate cyclase activity; and
- 7) modulation of phospholipase C activity,

the method comprising:

- a) contacting ~~thea~~ polypeptide ~~comprising the amino acid sequence of SEQ ID NO:1 or 4, or a fragment thereof,~~ with a test compound under conditions suitable for stimulation or inhibition~~modulation~~ of ~~the14273~~ polypeptide activity; and
- b) detecting stimulation or inhibition~~modulation~~ of ~~thea-14273~~ polypeptide activity by the test compound,

thereby identifying a compound which stimulates or inhibits the activity of the polypeptide.

42. (Currently Amended) A method for identifying a compound which stimulates or inhibits the activity of a polypeptide encoded by the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number PTA-1143, or a fragment thereof, wherein the activity is ~~modulates a 14273 polypeptide activity selected from the group consisting of:~~

- 1) binding to a G protein in response to ligand binding;
- 2) receptor protein phosphorylation in response to ligand binding;
- 3) binding to a ligand;
- 4) modulation of intracellular calcium concentration;
- 5) modulation of intracellular cAMP concentration;
- 6) modulation of adenylate cyclase activity; and
- 7) modulation of phospholipase C activity,

the method comprising:

- a) contacting ~~thea~~ polypeptide ~~eneoded by the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number PTA-1143, or a fragment thereof,~~ with a test

compound under conditions suitable for stimulation or inhibitionmodulation of the14273 polypeptide activity; and

b) detecting stimulation or inhibitionmodulation of thea-14273 polypeptide activity by the test compound,

thereby identifying a compound which stimulates or inhibits the activity of the polypeptide.

43-44. (Canceled)